Market Place
Sourcing Support
Blueprint Medicines Raises AYVAKIT® Revenue Guidance for 2024
30 Oct 2024 //
PR NEWSWIRE
Blueprint Medicines to Present at Upcoming Investor Conferences
10 Sep 2024 //
PR NEWSWIRE
Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit
30 May 2024 //
PR NEWSWIRE
Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance
02 May 2024 //
PR NEWSWIRE
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data
23 Feb 2024 //
PR NEWSWIRE
Blueprint boosts Ayvakit peak sales estimate to $2B
15 Feb 2024 //
FIERCE PHARMA
EC approves treatment for rare haematological disorder
13 Dec 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Blueprint Medicines` AYVAKYT® (avapritinib) Receives Positive CHMP Opinion
10 Nov 2023 //
PR NEWSWIRE
QIAGEN receives FDA approval for companion diagnostic to Blueprint™ AYVAKIT
07 Aug 2023 //
GLOBENEWSWIRE
FDA Approves AYVAKIT as Only Treatment for Indolent Systemic Mastocytosis
23 May 2023 //
PR NEWSWIRE
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
27 Feb 2023 //
ENDPTS
Blueprint lays out $1.5B expansion plan for Ayvakit
18 Feb 2023 //
FIERCE PHARMA
Blueprint Announces FDA Acceptance of Supplemental NDA for AYVAKIT
23 Jan 2023 //
PR NEWSWIRE
Cogent touts data on small subset of patients in bid to compete with Blueprint
12 Dec 2022 //
ENDPTS
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT
22 Nov 2022 //
PRESS RELEASE
Blueprint slips as it changes endpoint for trial to broaden Ayvakit label
11 Jun 2022 //
ENDPTS
EC Approves Blueprint Medicines` AYVAKYT for Advanced Systemic Mastocytosis
25 Mar 2022 //
PRNEWSWIRE
Blueprint Medicines` AYVAKYT Receives Positive CHMP Opinion in ASM/SM-AHN/MCL
28 Jan 2022 //
PRNEWSWIRE
CStone announced new drug approval of precision therapy AYVAKIT in GIST
28 Dec 2021 //
ASIAONE
Blueprint Medicines Reports Third Quarter 2021 Financial Results
28 Oct 2021 //
PRNEWSWIRE
Blueprint`S rare blood disease drug avapritinib receives US FDA approval
18 Jun 2021 //
PHARMABIZ
Blueprint challenges Novartis with new Ayvakit nod
18 Jun 2021 //
FIERCEPHARMA
FDA Approves Blueprint Medicines` AYVAKIT™ (avapritinib)
17 Jun 2021 //
PRNEWSWIRE
FDA approves avapritinib for advanced systemic mastocytosis
17 Jun 2021 //
FDA
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT®
31 Mar 2021 //
PRNASIA
Blueprint Medicines Submits Supplemental NDA to FDA for AYVAKIT™
17 Dec 2020 //
PRNEWSWIRE
Blueprint Medicines`s Ayvakyt (Avapritinib) Receives Approval In Europe
01 Oct 2020 //
EMA
Blueprint Medicines Ayvakyt (Avapritinib) Receives Approval in Europe
30 Sep 2020 //
EMA
Blueprint`s avapritinib OK`d in Europe for type of GI tract cancer
25 Sep 2020 //
SEEKING ALPHA
Genetron/CStone initiate study of companion diagnostic test for avapritinib
25 Sep 2020 //
GLOBENEWSWIRE
EMA committee recommends conditional MKT approval for Blueprint ’ avapritinib
06 Aug 2020 //
PHARMABIZ
EMA: Thumbs up for 11, down for 2 new medicines
25 Jul 2020 //
RAPS
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib
24 Jul 2020 //
PRESS RELEASE
Blueprint Medicines Announces The Lancet Oncology Showing Benefits of AYVAKIT™
29 Jun 2020 //
PRNEWSWIRE
Blueprint Medicines Presents Updated Part 1 from PIONEER Trial of Avapritinib
06 Jun 2020 //
BLUEPRINTMEDICINES
Blueprint`s Ayvakit gets FDA no-go in new stomach cancer use
16 May 2020 //
FIERCE PHARMA
Blueprint Medicines Announces Data Presentations Highlighting Progress
13 May 2020 //
PRNEWSWIRE
Blueprint Medicines Announces Part 1 Results from PIONEER Trial -Avapritinib
16 Mar 2020 //
PRE RELEASE
Blueprint Medicines to Present Updated Data from Ph2 PIONEER Trial Avapritinib
24 Feb 2020 //
PR NEWSWIRE
Blueprint Medicines Announces PDUFA Date Extension for NDA of Avapritinib
06 Feb 2020 //
PR NEWSWIRE
PANTHERx® Selected by Blueprint Medicines Corporation to Distribute AYVAKIT
17 Jan 2020 //
PR NEWSWIRE
Blueprint wins first FDA nod for a stomach cancer though not exactly
11 Jan 2020 //
FIERCE PHARMA
FDA approves the first targeted therapy to treat a rare mutation
10 Jan 2020 //
FDA
Ori Biotech Announces a $9.4M Seed Round
09 Jan 2020 //
PR NEWSWIRE
Blueprint’s Phase II avapritinib sparks concerns on risk-benefit profile
11 Dec 2019 //
CLINICALTRIALSARENA
Blueprint Medicines Announces Initial Data from Ph2 PIONEER Trial of Avapritinib
09 Dec 2019 //
PR NEWSWIRE
Blueprint Medicines to Present Initial Data from Phase 2 Trial of Avapritinib
06 Nov 2019 //
PR NEWSWIRE
First patient dosed for Phase I/II trial of avapritinib in advanced GIST
26 Aug 2019 //
BIOSPECTRUMASIA
Deciphera success sets up 2-horse race in gastrointestinal cancer
14 Aug 2019 //
BIOPHARMADIVE
Deciphera soars as phase 3 cancer data tee up FDA filing
13 Aug 2019 //
FIERCE BIOTECH
Blueprint Medicines Submits NDA to U.S. FDA for Avapritinib
19 Jun 2019 //
PR NEWSWIRE
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST
04 Jun 2019 //
PR NEWSWIRE
Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing
04 Jun 2019 //
FIERCE BIOTECH
CStone received IND approval in China for avapritinib Phase I/II
15 Apr 2019 //
PR NEWSWIRE
Avapritinib receives Phase III clinical trial approval for GIST in China
15 Feb 2019 //
BIOSPACE
Blueprint posts `impressive` data for lead candidate, but investors tepid
17 Nov 2018 //
BIOPHARMA DIVE
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib
21 Jun 2018 //
PR NEWSWIRE
Blueprint Medicines Announces Updated Data from Pha1 EXPLORER CTRLof Avapritinib
15 Jun 2018 //
PRESS RELEASE
